In the news release, "Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government," issued earlier today by Sinovac Biotech Ltd. over PR Newswire, we are advised by the company that the first sentence of the second paragraph should read," In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 21.06 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign," rather than, "In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 20.05 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign," as originally issued inadvertently. The complete, corrected release follows.
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 21.06 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In 2009, the Company completed the expansion of its production line used to manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing its annual production capacity by approximately 60%.
Mr.
About Sinovac
Sinovac Biotech Ltd. is a
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: aglynn@theruthgroup.com scarrington@theruthgroup.com Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: jmccargo@theruthgroup.com
------
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 20.05 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In 2009, the Company completed the expansion of its production line used to manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing its annual production capacity by approximately 60%.
Mr.
About Sinovac
Sinovac Biotech Ltd. is a
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact: Helen G. Yang Sinovac Biotech Ltd. Tel: +86-10-8289-0088 x9871 Fax: +86-10-6296-6910 Email: info@sinovac.com Investors: Amy Glynn/Stephanie Carrington The Ruth Group Tel: +1-646-536-7023/7017 Email: aglynn@theruthgroup.com scarrington@theruthgroup.com Media: Janine McCargo The Ruth Group Tel: +1-646-536-7033 Email: jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.